Detection of Survivin and COX-2 in Thyroid Carcinoma: Anaplastic Carcinoma Shows Overexpression of Nuclear Survivin and Low COX-2 Expression.
10.4132/KoreanJPathol.2012.46.1.55
- Author:
Young A KIM
1
;
Meesoo CHANG
;
Young Joo PARK
;
Ji Eun KIM
Author Information
1. Department of Pathology, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea. npol181@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Thyroid gland;
BIRC5 protein, human;
Cyclooxygenase 2;
Thyroid cancer, anaplastic
- MeSH:
Apoptosis;
Carcinoma;
Carcinoma, Papillary;
Cyclooxygenase 2;
Disease Progression;
Goiter;
Immunohistochemistry;
Inhibitor of Apoptosis Proteins;
Thyroid Gland;
Thyroid Neoplasms
- From:Korean Journal of Pathology
2012;46(1):55-60
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Overexpression of survivin, a member of the inhibitors of apoptosis protein, has been reported in various carcinomas, and its interaction with cyclooxygenase 2 (COX-2) results in accelerated tumor progression. The purpose of this study is to investigate the immunohistochemical expression of survivin and COX-2 in benign and malignant thyroid tissues and to define its association with pathologic and clinical features. METHODS: We examined expression of survivin and COX-2 by immunohistochemistry in 334 benign and malignant thyroid tissues and evaluated their clinical significance. RESULTS: Expression of survivin showed an increase along the spectrum of thyroid carcinoma progression; rarely positive in adenomatous goiter, moderately positive in papillary carcinoma, and strongly positive in anaplastic carcinoma (AC). Papillary microcarcinoma revealed the highest COX-2 positivity and AC demonstrated the lowest positivity among thyroid cancers. Node negative carcinomas showed higher COX-2 expression than node positive tumors. Survivin expression did not correlate with COX-2. CONCLUSIONS: Our findings suggest that survivin overexpression may be related to the pathogenesis of AC and can be a predictor of disease progression. COX-2 may be involved in the early phase of thyroid carcinoma.
